Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma

BACKGROUND: Glioblastoma (GBM) has poor prognosis despite aggressive treatment. Dendritic cell (DC) vaccines are promising, but widespread clinical use has not been achieved, possibly reflecting manufacturing issues of antigen choice and DC potency. We previously optimized vaccine manufacture utiliz...

Descripción completa

Detalles Bibliográficos
Autores principales: Parney, Ian F, Anderson, S Keith, Gustafson, Michael P, Steinmetz, Susan, Peterson, Timothy E, Kroneman, Trynda N, Raghunathan, Aditya, O’Neill, Brian P, Buckner, Jan C, Solseth, Mary, Dietz, Allan B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9370382/
https://www.ncbi.nlm.nih.gov/pubmed/35967100
http://dx.doi.org/10.1093/noajnl/vdac089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9370382/
https://www.ncbi.nlm.nih.gov/pubmed/35967100
http://dx.doi.org/10.1093/noajnl/vdac089

Ejemplares similares